Fujifilm Biotechnologies inaugurated its expanded Teesside, UK campus after a roughly £400 million investment, unveiling what the company says is the largest single-use biopharmaceutical CDMO facility in the country. The expansion adds 2,000 L and 5,000 L single-use bioreactors and up to 19,000 L of single-use capacity, alongside a 110,000 sq. ft. GMP manufacturing footprint and a Bioprocess Innovation Centre (BIC UK) for continuous process development. Fujifilm positioned the site to accelerate antibody and complex-molecule manufacture for oncology, neurodegenerative and rare-disease programs and to streamline technology transfer through its kojoX modular platform. Executives framed the investment as a global supply‑chain and scale play, aligning processes with Fujifilm’s Toyama, Japan facility to reduce transfer time and support mid-scale clinical and commercial programs. Manufacturers and biotech sponsors should view this as a material increase in European single-use capacity that could ease development timelines for cell‑derived and antibody therapeutics, while intensifying competition among CDMOs for mid-market campaigns. Source: Fujifilm corporate release and site opening coverage.